about
Functional, biophysical, and structural bases for antibacterial activity of tigecyclineGlobal Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 GeneHydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteriaEffect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infectionsGlobal incidence of carbapenemase-producing Escherichia coli ST131.Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities.AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.Identification and sequence of a tet(M) tetracycline resistance determinant homologue in clinical isolates of Escherichia coli.Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.Late stage antibacterial drugs in the clinical pipeline.Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing resultsGlobal Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-AvibactamEfficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.β-Lactams and β-Lactamase Inhibitors: An Overview.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA-LacZ reporter fusion system.Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.Uses of Staphylococcus aureus GeneChips in genotyping and genetic composition analysis.In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and ResisIn vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm modelStructural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteriaCeftriaxone-resistant salmonella infection acquired by a child from cattle.AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaCharacterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
P50
Q24548264-A500D5FC-D398-487A-BBC7-339BDF819087Q28112087-9B9CB587-9244-49CB-8063-2A15EEFAB58DQ28169095-D15B9B87-5DD6-4460-89AF-CA150AAE6499Q33935354-D01A81A6-CCC9-4B45-8517-ED69FD151950Q34110412-DF39B5BF-C61B-49CD-BB2D-D5D3F2D80C03Q34123752-7164D992-3B1A-4279-A197-33EF165BBFCDQ34352287-03003619-A619-4BF1-8208-B4709E4C72EFQ34426812-4D66ED45-236F-494F-99ED-7CFA3F0750B6Q34722061-48E280D4-DCD5-4E08-A0C5-7FAE57004156Q34822277-1DE1860C-FEA0-496C-A5D4-FBB043862266Q35130141-93147A72-7F37-40FF-9777-CECDB7976444Q36492132-EC4F9E4C-08B4-4CCE-AC6F-AE1D04D96CD2Q36571962-390DA5AE-CCB6-49EF-9E98-F91F20ABC73BQ36644582-04F32045-C466-482C-A579-99659B2A715FQ36976704-5D297C7F-9AAD-4481-813A-DDF8ABE61E9EQ37099549-C4D4DE22-981E-45FA-AB0C-435FDC3B2398Q37119944-B9FB845D-C01F-400E-835B-07137F0B1648Q37144879-F03B2C9C-2436-44A3-B049-A7F1EFED71A1Q37203734-DCA0757C-4E2D-44EC-9A10-BFD76C9F9B3CQ37624562-85405313-36C2-4446-9DF5-F5B9F405077BQ38872374-CE310477-52B9-457C-BD70-050999D9C16CQ39001350-A036FA46-A8A3-4F76-8AD5-BEB5D85D15E3Q39473957-FEB043C8-8606-4ACA-9759-9C380611C3D9Q39678750-C8166CE6-8851-41D1-9D2D-FE5C214CD540Q39687830-753BB89A-8136-468A-9311-A0930466445AQ39731888-414A5870-660F-4D8A-8494-599B53FBAA76Q39843388-4F810F52-D5C6-4819-89F2-69DF5309BCE7Q39923839-C466F60C-3614-4833-9A30-8BE21401F34AQ39989567-F50646E3-17A6-4A86-8236-FEA0B6DCD895Q40166206-BAD923AC-3D77-459E-A67C-6576FBA96DCBQ40276518-52771397-0C7A-48A9-A548-8F44D9735D2CQ40345143-C6D8D388-45ED-4D52-B5BC-7ECF699B7E37Q40617746-BEACFFCA-A4C0-4360-8821-822688AAB807Q40622160-8BAB7811-1B46-4386-BCB7-EA6481A61266Q40622609-F075BFA6-9FD5-4357-AB28-986775E9E1ECQ41005771-13983506-391E-408B-8865-B34A66887332Q41098625-4C2040E1-E86D-4C9D-A653-B168A8A79C7DQ41240109-B01092DE-EE4B-49AB-9171-C0B32E80B354Q41668866-694922FD-F169-4A1B-A253-CB1118303114Q41813766-CB3CB3BA-EDF5-45CA-BEC6-BB2BCF453E71
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patricia A Bradford
@nl
Patricia A Bradford
@sl
Patricia A. Bradford
@en
Patricia A. Bradford
@es
type
label
Patricia A Bradford
@nl
Patricia A Bradford
@sl
Patricia A. Bradford
@en
Patricia A. Bradford
@es
prefLabel
Patricia A Bradford
@nl
Patricia A Bradford
@sl
Patricia A. Bradford
@en
Patricia A. Bradford
@es
P106
P1153
7005679687
P21
P31
P496
0000-0002-1285-2978